影响脑胶质瘤患者预后的固有免疫分子筛选与验证

Screening and Validation of Innate Immune Molecules Affecting the Prognosis of Glioma Patients

目的筛选与验证影响脑胶质瘤患者预后的固有免疫分子。方法①检索数据库获得固有免疫相关分子,检索数据库中的胶质瘤差显基因,通过数据库分析获得影响预后的基因,将上述三类基因取交集,获得影响脑胶质瘤患者预后的固有免疫分子。②TCGA数据库作为内部验证,NCBI数据库作为外部检验,分析其在不同级别胶质瘤中的差异表达及对生存时间的影响。结果筛选出差显固有免疫基因CD58,通过分析,发现其表达水平随脑胶质瘤病理级别升高而升高,CD58表达越高患者生存期越短(P<0.001)。结论CD58可以作为脑胶质瘤诊断及预后评价的参考指标,有可能成为新的脑胶质瘤免疫治疗靶点。

Objective To screen and verify the innate immune molecules that affect the prognosis of glioma patients.Methods 1.Search the database to obtain innate immunity-related molecules,search the database for differentially expressed glioma genes,and obtain the genes that affect the prognosis through database analysis.The above three types of genes are intersected to obtain the innate immunity that affects the prognosis of glioma patients.molecular.2.The TCGA database was used as an internal validation,and the NCBI database was used as an external test to analyze its differential expression in different grades of glioma and its impact on survival time.Results The differentially significant innate immune gene CD58 was screened out.Through analysis,it was found that its expression level increased with the increase of the pathological grade of glioma,and the higher the expression of CD58,the shorter the survival time of patients(P<0.001).Conclusion CD58 can be used as a reference index for the diagnosis and prognosis evaluation of glioma,and it may become a new target for immunotherapy of glioma.